Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD

Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis

(2016) S. Singh et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Comparative Effectiveness and Safety of Anti–Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn’s Disease

(2016) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

Anti-TNF Monotherapy for Crohn’s Disease: a 13-year Multicentre Experience

(2016) Laurent Peyrin-Biroulet et al.   Journal of Crohns & Colitis

Long-Term Response Rates to Infliximab Therapy for Crohn’s Disease in an Outpatient Cohort

(2016) Christopher W Teshima et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONICpost hocanalysis

(2015) J.-F. Colombel et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab

(2015) Henit Yanai et al.   Clinical Gastroenterology and Hepatology

Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis

(2015) Glen S. Hazlewood et al.   GASTROENTEROLOGY

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus

(2015) Brian Bressler et al.   GASTROENTEROLOGY

Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn’s Disease

(2015) Casper Steenholdt et al.   Journal of Crohns & Colitis

Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease

(2015) Konstantinos Papamichael   WORLD JOURNAL OF GASTROENTEROLOGY

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease

(2014) Niels Vande Casteele et al.   GUT

Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study

(2014) Christopher Ma et al.   Journal of Crohns & Colitis

Comparative Efficacy of Biologic Therapy in Biologic-Naïve Patients With Crohn Disease: A Systematic Review and Network Meta-analysis

(2014) Siddharth Singh et al.   MAYO CLINIC PROCEEDINGS

Time of infliximab therapy initiation and dose escalation in Crohn’s disease

(2014) Mindy CW Lam   WORLD JOURNAL OF GASTROENTEROLOGY

Biological therapies in Crohn’s disease: are they cost-effective? A critical appraisal of model-based analyses

(2014) Monia Marchetti et al.   Expert Review of Pharmacoeconomics & Outcomes Research

American Gastroenterological Association Institute Guideline on the Use of Thiopurines, Methotrexate, and Anti–TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease

(2013) Jonathan P. Terdiman et al.   GASTROENTEROLOGY

Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

(2013) Remo Panaccione et al.   GASTROENTEROLOGY

Effects of Discontinuing Anti–Tumor Necrosis Factor Therapy During Pregnancy on the Course of Inflammatory Bowel Disease and Neonatal Exposure

(2012) Zuzana Zelinkova et al.   Clinical Gastroenterology and Hepatology

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study

(2012) Mirthe Emilie van der Valk et al.   GUT

Implementing changes in clinical practice to improve the management of Crohn's disease

(2012) Remo Panaccione et al.   Journal of Crohns & Colitis

Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

(2011) Vincent Billioud et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Long-term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT-1 and -2 Extension Studies

(2011) Walter Reinisch et al.   INFLAMMATORY BOWEL DISEASES

Direct Medical Cost of Managing IBD Patients: A Canadian Population-based Study

(2011) Charles N. Bernstein et al.   INFLAMMATORY BOWEL DISEASES

Long-term Durability of Infliximab Treatment in Crohnʼs Disease and Efficacy of Dose “Escalation” in Patients Losing Response

(2011) María Chaparro et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Intensification of infliximab therapy in Crohn's disease: Efficacy and safety

(2011) M.Chaparro et al.   Journal of Crohns & Colitis

Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis

(2011) John Paul Leombruno et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Response?

(2010) Geert R D'Haens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

(2010) Waqqas Afif et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn’s disease in patients treated with infliximab

(2009) G. BOUGUEN et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

(2009) Javier P Gisbert et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study

(2009) Pál Miheller et al.   BMC GASTROENTEROLOGY

Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab

(2009) William J. Sandborn et al.   GASTROENTEROLOGY

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort

(2008) F Schnitzler et al.   GUT